A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Completed · Phase 2

Conditions studied: Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

In brief

CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.

Key facts

Study ID

NCT00034827

Run by

Pfizer

People needed

172

Starts

2002-01-01

Expected to finish

2003-05-01

Last updated by the study team

2007-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are at least 18 years or older who have pathological or hiostological confirmation of colorectal, nonsmall cell lung cancer, breast, or pancreas cancer.
• No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast no prior chemotherapy for pancreas cancer.
• Original or recent tumor tissue must be available.
• Patients must have been off prior chemoptherapy for 4 weeks and radiation for 3 weeks.
• Patients must have adequate renal, liver, and bone marrow function, not have serious infection or life-threatening illness (unrelated to tumor).
• Must be able to swallow capsules and not have gastrointestinal disorders that may affect absorption of the drug.

You may not qualify if…

• Unstable medical condition
• prior chemotherapy within 4 week of screening
• series infection
• other tumor types
• ECOG performance status of 3 or 4.

Where it is running

• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Blendora, California, United States
• Pfizer Investigational Site — Glendale, California, United States
• Pfizer Investigational Site — Huntington Beach, California, United States
• Pfizer Investigational Site — Long Beach, California, United States
• Pfizer Investigational Site — Los Alamitos, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Mission Hills, California, United States
• Pfizer Investigational Site — Northridge, California, United States
• Pfizer Investigational Site — Oxnard, California, United States
• Pfizer Investigational Site — Pasadena, California, United States
• Pfizer Investigational Site — Pomona, California, United States
• Pfizer Investigational Site — Rancho Cucamonga, California, United States
• Pfizer Investigational Site — Redondo Beach, California, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Ventura, California, United States
• Pfizer Investigational Site — West Covina, California, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Decatur, Georgia, United States
• Pfizer Investigational Site — Macon, Georgia, United States
• Pfizer Investigational Site — Crestview Hills, Kentucky, United States
• Pfizer Investigational Site — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.